Another study of 164 prostate cancer patients treated with RT with or without N-ADT, 2-year BCF was 11.1% for those with an PSA value ≤10 ng/mL, 23.1% for 10–19.9 ng/mL, 29.6% for 20–99.9 ng/mL, and 75% for ≥100 ng/mL [22]. This evidence concerns the gene KLK3 and prostate cancer.